T Cells and T Cell-Derived Cytokines as Pathogenic Factors in the Nonallergic Form of Atopic Dermatitis  by Akdis, Cezmi A. et al.
T Cells and T Cell-Derived Cytokines as Pathogenic Factors
in the Nonallergic Form of Atopic Dermatitis
Cezmi A. Akdis,* Mu¨beccel Akdis,* Dagmar Simon,† Birgit Dibbert,* Martina Weber,* Stephanie Gratzl,*
Oliver Kreyden,‡§ Rainer Disch,† Brunello Wu¨thrich,§ Kurt Blaser,* and Hans-Uwe Simon*
*Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland; †Clinic for Dermatology and Allergy (Alexanderhausklinik), Davos,
Switzerland; ‡High-Altitude Clinic Davos-Clavadel, Davos, Switzerland; §Department of Dermatology, University of Zu¨rich, Zu¨rich, Switzerland
A subgroup of patients with atopic dermatitis are
known to have normal serum total immunoglobulin
E levels, undetectable specific immunoglobulin E, and
negative skin prick tests towards allergens. This form
of the disease has been termed nonallergic atopic
dermatitis. In this study, we found that, among 1151
chronic atopic dermatitis patients, about 10% had
normal serum immunoglobulin E levels with no
evidence for immunoglobulin E sensitization. We
investigated immunologic mechanisms of patients
with ‘‘allergic’’ and ‘‘nonallergic’’ atopic dermatitis
using peripheral blood and skin biopsy samples. Our
data suggest that T cells are likely involved in the
pathogenesis of both forms of atopic dermatitis. Skin
T cells equally responded to superantigen, staphylo-
coccal enterotoxin B, and produced interleukin-2,
interleukin-5, interleukin-13, and interferon-g in both
forms of the disease. Interleukin-4, however, was not
detectable in the skin biopsies of both atopic dermatitis
Atopic dermatitis (AD) is a chronic relapsing inflam-matory skin disease characterized by typicallydistributed eczematous skin lesions with licheni-fication, pruritic excoriations, severely dry skin, anda susceptibility to cutaneous infections (Hanifin and
Rajka, 1980; Rudikoff and Lebwohl, 1998). Several lines of
evidence suggest the contribution of immunologic mechanisms in
the pathogenesis of AD. The skin lesions of AD patients are
infiltrated by activated T cells, eosinophils, and antigen-presenting
Langerhans cells that bind and present immunoglobulin (Ig) E-
complexed allergens on their surface (Reinhold, 1992; Ka¨gi et al,
1994). In addition, activation of peripheral blood T cells that
preferentially secrete T helper (Th) 2 cytokines and help B cells to
produce large amounts of immunoglobulin (Ig) E has previously
been reported to be associated with this skin disease (Walker et al,
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types and was secreted in very low amounts by T cells
cultured from the skin biopsies. Moreover, skin T cells
from nonallergic atopic dermatitis patients expressed
lower interleukin-5 and interleukin-13 levels compared
with allergic atopic dermatitis patients. Accordingly,
T cells isolated from skin biopsies of atopic dermatitis,
but not from the nonallergic atopic dermatitis, induced
high immunoglobulin E production in cocultures with
normal B cells that was mediated by interleukin-13.
In addition, B cell activation with high CD23 expres-
sion was observed in the peripheral blood of atopic
dermatitis, but not nonallergic atopic dermatitis
patients. These data suggest, although high numbers
of T cells are present in lesional skin of both types, a
lack of interleukin-13-induced B cell activation and
consequent immunoglobulin E production in non-
allergic atopic dermatitis. Key words: atopic dermatitis/
cytokines/immunoglobulin E/superantigen/T cells. J Invest
Dermatol 113:628–634, 1999
1993; Hamid et al, 1994; Akdis et al, 1997; Fujimura et al, 1997;
Nakazawa et al, 1997).
Although most of the patients with AD show high concentrations
of total and allergen-specific IgE in blood and skin, some of the
patients have normal total IgE levels and negative serum allergen-
specific IgE (Wu¨thrich, 1978). Diagnostic criteria of AD by Hanifin
and Rajka (1980) or Williams et al (1994) can be fulfilled in the
absence of elevated total IgE and specific IgE to food or environ-
mental allergens. This suggests that elevated IgE levels and IgE
sensitization are not prerequisites in the pathogenesis of the disease.
The subgroup of AD patients with normal IgE levels and without
specific IgE sensitization has been termed nonallergic form of AD
(NAD) or intrinsic-type AD (Ka¨gi et al, 1994). In this study, we
reserved the term ‘‘AD’’ only for the patients with features of atopy.
Patients were classified into the NAD group when they fulfilled
the criteria of Hanifin and Rajka (1980), but did not exhibit any
allergen-specific IgE sensitization and had normal serum total
IgE levels.
In this study, we investigated immunoregulatory mechanisms
that are possibly involved in the pathogenesis of NAD in comparison
with AD. The results suggest that T cells and T cell-derived
cytokines do not only play an important part in allergic AD, but
also in NAD. One important difference between the two forms of
AD appears to be the different capacity of skin T cells to induce
IgE production in B cells, possibly due to decreased interleukin
(IL) -13 production in NAD.
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MATERIALS AND METHODS
Subjects In the time period from January 1997 until June 1998, we
recruited 1151 patients among the three clinics in Davos and Allergy Unit
of Zu¨rich University, Zu¨rich, Switzerland who fulfilled the diagnostic
criteria of Hanifin and Rajka (1980). On the basis of the case history, total
and specific IgE levels and skin prick tests, the subjects were further divided
into AD and NAD patients. Characteristics of the AD patients were total
serum IgE levels above 150 kU per liter and/or positive radioallergosorbent
test or immunoassay (Pharmacia Diagnostics AG, Uppsala, Sweden), as
well as a positive patient’s history for allergic diseases. Usually, these patients
also had positive skin prick tests towards common environmental allergens.
In many cases, however, skin prick tests could not be performed due to
the severity of skin symptoms. Patients were termed NAD when they had
a negative history for allergic diseases, low levels of total IgE (,150 kU
per liter), no elevated specific IgE antibodies, and no immediate-type skin
reactions towards a routine panel of relevant aeroallergens and food
allergens. The possibility that the patients might have allergic contact
dermatitis was ruled out by multiple evaluations of the patients at different
times, disease history, clinical course, and features of the disease. Two of
the patients were skin patch tested to exclude allergic contact dermatitis.
For immunologic analysis, we obtained 10 ml of ethylenediamine
tetraacetic acid anti-coagulated blood and skin biopsies from nine patients
with AD (two female, seven male, mean age: 37 y) and eight patients with
NAD (four female, four male, mean age: 49 y). One patient from the AD
group and one patient from NAD group had asthma. Three patients with
AD had allergic rhinoconjunctivitis. The clinical material was collected
under standard hospital approved protocols. Skin biopsy specimens were
obtained from acute AD lesions of less than 5 d onset. We also collected
a group of six healthy individuals (three male, three female, mean
age: 39 y) with no history or signs of atopy as a control group for
immunophenotyping. All AD and NAD patients suffered from an acute
exacerbation of their chronic disease. Duration of their disease was 18 6 4 y
in AD and 16 6 6 y in NAD (mean 6 SEM). There was no significant
difference in the age and age of onset between the AD versus NAD groups.
Serum IgE levels were 12333 6 5663 kU per liter in AD and 42 6 13 kU
per liter in NAD. The patients have not been treated with oral or topical
steroids for at least 1 wk prior to vein puncture and skin biopsy. Informed
consent was obtained from all patients and control individuals, and the
study was approved by the Swiss Academy of Medical Science represented
by the Medical Ethics Committee of Davos.
Media, reagents, and antibodies Complete culture medium was RPMI
1640 supplemented with 2 mM L-glutamine, penicillin/streptomycin, and
fetal bovine serum (all from Life Technologies, Basel, Switzerland). All
conjugated monoclonal antibodies (MoAb) for flow-cytometric analysis
were purchased from Coulter (Hialeah, FL), Immunotech Ltd. (Marseilles,
France), or Pharmingen (San Diego, CA). Anti-CD2 (4B2 and 6G4) and
anti-CD28 (15E8) MoAb were from the Red Cross Blood Transfusion
Service in Amsterdam (the Netherlands). Anti-CD3 was produced by
clone CRL 8001 obtained from ATCC (Washington, DC). Biotin-labeled
MoAb and avidin was from Sigma (St. Louis, MO). Neutralizing anti-IL-4
MoAb (8F12) was provided by Novartis (Basel, Switzerland). Neutralizing
anti-IL-13 MoAb (JES8–5A2 and JES10–2F9) and mutant IL-4 antagonist
(Y124D; with inhibitory activity for both IL-4 and IL-13) were provided
by DNAX Research Institute (Palo Alto, CA). The antibodies for
immunohistochemistry, anti-IL-2, anti-interferon (IFN) -γ, and anti-IL-13
MoAb were from R&D Systems Europe Ltd. (Abingdon, U.K.). Anti-
IL-5 was a kind gift of Dr J. Tavernier (Gent, Belgium). Anti-cutaneous
lymphocyte-associated antigen (CLA) MoAb was from Pharmingen, and
anti-eosinophilic cationic protein (ECP; EG1) was from Pharmacia
(Uppsala, Sweden). Anti-CD4 MoAb was obtained from Novocastra
Laboratories (Newcastle, U.K.). Anti-CD8 and control MoAb were pur-
chased from Dako (Zug, Switzerland).
Analysis of leukocytes and lymphocyte subsets Blood leukocyte and
differential counts were determined by automatic blood count analysis
(Technicon H1, Technicon, Tarrytown, NY). To determine lymphocyte
subsets, specific binding of MoAb was analyzed by direct immunofluores-
cence using standard methods (Oehling et al, 1997). The flow-cytometric
analysis was performed by an EPICS XL (Coulter).
Identification of the inflammatory cell infiltrate in the
skin Inflammatory cells were identified using lineage-specific MoAb
and immunohistochemistry. Briefly, fresh skin tissues were fixed in 4%
paraformaldehyde solution. Paraffin sections were mounted on poly L-
lysin-coated slides, stored at room temperature, deparaffinized in xylene,
and rehydrated through graded concentrations of ethanol before use.
Antigen retrieval was achieved by the microwave oven heating procedure.
CD4 and CD8 stainings were performed with the Dako catalyzed signal
amplification (CSA) system according to the manufacturer’s instructions
(Dako). CLA stainings were done using the Zymed Lab-SA System (Zymed
Laboratories, South San Francisco, CA). ECP stainings were performed
using the APAAP technique as described previously (Simon et al, 1997).
Purification and stimulation of skin T cells The skin biopsy specimens
from four AD patients and four NAD patients were minced with two
scalpels; no proteolytic enzymes were used. The T cells of the obtained
skin biopsy fractions were stimulated in complete culture medium with
25 U IL-2 per ml and the following combination of MoAb to T cell
surface molecules: anti-CD2 (4B2 and 6G4, each 0.5 µg per ml), anti-
CD3 (5 µg per ml), and anti-CD28 (1 µg per ml) (Akdis et al, 1999).
After 7–10 d, this treatment resulted in an expansion of skin T cells. These
cells were washed and used for functional assays (IgE production), as well
as for proliferative response to super antigens and cytokine analysis by flow
cytometry and enzyme-linked immunosorbent assay (ELISA). T cells
isolated from skin of AD and NAD patients were stimulated with different
doses of staphylococcal enterotoxin B (SEB) in 96-well flat bottomed
plates (5 3 104/200 µl per well) in triplicates by using rad irradiated
autologous peripheral blood mononuclear cells (PBMC) (5 3 104) as
antigen-presenting cells. [3H]thymidine incorporation was measured after
3 d following an 8 h incubation with 1 µCi per well of [3H]thymidine.
The plates were harvested on glass-fiber plates and radioactivity was
measured in a Beta Plate Reader (Pharmacia-Wallac, Turku, Finland). For
the determination of cytokine production, the in vitro-expanded skin T cells
(0.5 3 106 per ml; 48-well plates in triplicates) were again stimulated with
anti-CD2, anti-CD3, and anti-CD28 MoAb for 72 h, and the supernatants
were harvested and frozen at –80°C until ELISA measurements. For
intracellular staining of cytokines, the cells were stimulated with the same
combination of MoAb for 16 h before flow cytometric analysis.
Measurements of cytokine levels
ELISA The solid-phase sandwich ELISA for IFN-γ, IL-4, IL-5, and IL-10
were performed as described previously (Akdis et al, 1996, 1997, 1998).
IL-13 and granulocyte-macrophage colony-stimulating factor were meas-
ured using commercial kits according to the manufacturer’s instructions
(R&D Systems).
Immunohistochemistry All cytokine stainings were performed using the
APAAP technique as previously described (Yousefi et al, 1995; Simon et al,
1997). Sections were lightly counterstained with hematoxylin, mounted,
and examined under a Zeiss Axioscope at a magnification of 3400 or
31000. The intensities of the stainings were evaluated by two independent
investigators from low (0) to high (6).
Flow cytometry During the last 14 h of cell culture, 1 µM monensin was
added. The cells were washed with phosphate-buffered saline and surface-
stained with phycoerythrin Texas red-labeled anti-CD4 or anti-CD8
MoAb, followed by fixing and permeabilizing of the cells with a formalde-
hyde/saponin solution (Ortho Permeafix, Ortho Diagnostic Systems, Rari-
tan, NJ). After washing with phosphate-buffered saline containing 5% fetal
bovine serum, 1.5% bovine serum albumin, and 0.0055% ethylenediamine
tetraacetic acid, the cells were counter-stained with 0.5 µg per ml
phycoerythrin- or fluorescein isothiocyanate-conjugated control, anti-IL-4,
anti-IL-5, anti-IL-13, and anti-IFN-γ MoAb for 30 min at 4°C. The flow-
cytometric analysis was performed using an EPICS XL (Coulter).
IgE production in vitro PBMC from normal control individuals were
depleted from CD3-, CD4-, and CD8-bearing cells by negative selection
using a magnetic cell separation system (MACS; Miltenyi Biotec, Bergisch-
Gladbach, Germany) as described previously (Akdis et al, 1997). T cell-
depleted PBMC (0.9 3 105) were cocultured with anti-CD2-, anti-CD3-,
and anti-CD28-stimulated skin T cells (0.1 3 105) derived from four AD
and four NAD patients. IgE was determined in supernatants harvested after
12 d. Inhibition of IgE production was attempted by addition of neutralizing
MoAb to IL-4 or IL-13 (both at 10 µg per ml) (Akdis et al, 1997). The
IL-4 and IL-13 antagonist Y124D was used at 100 ng per ml (Zurawski
and De Vries, 1994). Mouse IgG1 (10 µg per ml) was used as a control.
IgE concentrations were measured by ELISA as described previously (Akdis
et al, 1996, 1997). All experiments were performed in triplicate.
Statistics All data are expressed as means 6 SD. Statistical analysis was
performed using the Student’s t test (*p , 0.05).
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Table I. Peripheral blood leukocyte and lymphocyte
subpopulationsa
Controls AD NAD
Leukocytes (per µl) 6850 6 1331 7544 6 2952 7525 6 3318
Lymphocytes (%) 34 6 8 37 6 19 36 6 7
CD31 (%) 74 6 4 74 6 5 73 6 8
CD31CD41 (%) 47 6 6 50 6 6 45 6 15
CD31CD81 (%) 23 6 3 23 6 6 25 6 12
CD4/CD8 ratio 2.1 6 0.6 2.4 6 0.8 2.5 6 1.8
CD161 (%) 11 6 4 6 6 4 10 6 7
CD191 (%) 10 6 6 15 6 4 13 6 5
CD41HLA-DR1 (%) 7 6 5 14 6 12 7 6 3
CD41CD251 (%) 18 6 6 26 6 13 27 6 9
CD81HLA-DR1 (%) 6 6 4 16 6 24 19 6 16
CD81CD251 (%) 1 6 1 7 6 17 2 6 2
CD191CD231 (%) 24 6 16 67 6 12* 21 6 12
Monocytes (%) 4 6 3 6 6 2 7 6 4
CD141HLA-DR1 (%) 96 6 5 94 6 4 93 6 5
Neutrophils (%) 60 6 8 47 6 14 53 6 9
Eosinophils (%) 2 6 1 10 6 5* 4 6 3*
aThese data are mean 6 SD from six normal control individuals, nine AD patients,
and eight NAD patients. *Significantly different values from those of normal control
individuals (p , 0.05).
RESULTS
Peripheral blood leukocyte and lymphocyte subpopulations
in AD and NAD We investigated 1151 patients who fulfilled
the criteria of Hanifin and Rajka (1980) within a time period of
18 mo. From these patients, 116 NAD patients were identified.
Accordingly, in this study about 10% of all atopic dermatitis patients
belonged to the nonallergic group. The immunologic data described
here were obtained from nine AD and eight NAD patients.
The leukocyte differential counts revealed a characteristic blood
eosinophilia in both types of atopic dermatitis. It was more
pronounced in AD compared with NAD patients, although it
did not show any statistically significant difference (Table I).
Immunophenotyping using flow cytometry revealed increased
numbers of CD231 B cells in AD, but not in NAD patients, in
agreement with previously published work (Wu¨thrich, 1989; Ka¨gi
et al, 1994). In contrast, CD41 and CD81 T cells expressed
increased activation markers (HLA-DR and CD25) in both AD
and NAD patients, although the differences had no statistical
significance.
T cells infiltrate into the skin of AD and NAD patients To
identify the inflammatory cells present in lesional skin, we performed
immunohistochemistry using skin biopsies from AD and NAD
patients. T cells were identified with anti-CD4, anti-CD8, and
anti-CLA MoAb, whereas eosinophils were stained with an anti-
ECP MoAb. As shown in Fig 1 and Table II, AD and NAD
patients exhibited similar cellular infiltrates in their lesional skins.
The majority of the cells represented CD41 and CD81 cells,
suggesting an important role for T cells in both groups. The CD4/
CD8 ratios between blood and skin appeared to be similar,
suggesting that both CD41 and CD81 T subpopulations are equally
recruited into the inflammatory sites of AD and NAD patients. In
allergic AD, the pivotal role of CD45RO1 (memory/effector)
T cells expressing the skin homing receptor, the CLA was demon-
strated. Almost all T cells in benign and malignant cell infiltrations
of the skin express CLA molecule on their surface (Picker et al,
1990, 1991). As previously observed in AD and other dermatologic
diseases (Picker et al, 1990), most of the skin-infiltrating T cells of
NAD patients were CLA positive. Eosinophil content of skin
lesions were low in comparison with T cells. ECP positive cells
were 15.1 6 18.3 per mm2 skin in AD and 8.3 6 11.4 per mm2
skin in NAD (mean 6 SD) (Table II).
In vivo expression of cytokines in lesional skin of AD
and NAD patients It has been repeatedly suggested that Th2
Figure 1. Inflammatory cells in lesional skin of AD and NAD
patients. The majority of the cells represented CD41 and CD81 T cells.
Many of the T cells were CLA1. The eosinophil infiltration was much
less in comparison with the T cell infiltration. No differences were observed
between AD and NAD patients. Data are shown in Table II.
cytokines play an important part in AD and other atopic diseases
(Hamid et al, 1994; Akdis et al, 1997; Fujimura et al, 1997;
Nakazawa et al, 1997). Therefore, we investigated the Th1/Th2
cytokine pattern of AD and NAD patients using immunohistochem-
istry. As shown in Fig 2, Table II, both Th1 (IL-2 and IFN-γ)
and Th2 (IL-5 and IL-13) cytokines were expressed by inflammatory
cells of AD and NAD patients. Higher IL-5 and IL-13 expressions
were observed in AD than in NAD, although it did not reach
statistical significance. As the cellular infiltrate mostly contained
T cells (Table II), it is likely that these cells were the main cellular
source for these cytokines. Interestingly, IL-4 was neither detectable
in skin lesions of AD nor NAD patients.
Superantigen response and cytokine expression by skin
T cells isolated from lesional skin of AD and NAD
patients To further investigate the expression of cytokines by
skin T cells, we measured cytokine levels by flow cytometry and
ELISA. Owing to the low cell numbers obtained from skin biopsies,
however, T cells had to be expanded in vitro. Cells were stimulated
with a combination of anti-CD2, anti-CD3, and anti-CD28 MoAb
in the presence of IL-2 for optimal T cell proliferation. The in vitro-
expanded T cells were then analyzed for intracytoplasmic cytokine
expression. As assessed by flow cytometry, T cells from both AD
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Table II. Inflammatory cells and cytokines in lesional skin of AD and NAD patientsa
CD4 CD8 CD4/CD8 ECP CLA (%)
AD 579 6 222 290 6 127 2.11 6 1.07 15.1 6 18.3 62.9 6 23.5
NAD 527 6 305 274 6 147 2.00 6 0.66 8.3 6 11.4 59.3 6 23.9
IL-2 IFN-γ IL-4 IL-5 IL-13
AD 2.75 6 1.83 1.00 6 1.07 0.00 2.50 6 1.77 3.00 6 1.20
NAD 2.13 6 0.99 0.50 6 0.76 0.00 1.13 6 1.25 2.13 6 1.36
aThe skin-infiltrating cells were determined by immunohistochemistry per mm2 skin section as described in Materials and Methods. These data are mean 6 SD from nine
AD patients, and eight NAD patients The intensity of the cytokine stainings were independently evaluated by two investigators (M.W. and S.G.) from low (0) to high (6) grade.
Figure 2. IL-13, but not IL-4, is expressed in lesional skin of AD
and NAD patients. The positive control for IL-4 was a bladder cancer
tissue expressing IL-4. In average, the expression of IL-13 was less in NAD
in comparison with AD patients. All data regarding cytokine expression
are shown in Table II.
and NAD patients did not express detectable amounts of IL-4
protein (Fig 3), confirming the data obtained by immunohisto-
chemistry (Fig 2, Table II). Moreover, significant amounts of IL-5
were usually detected in T cells from AD (CD41 . CD81), but
not NAD patients (Fig 3). In contrast, IFN-γ was frequently
detected in T cells from NAD (CD81 . CD41), but not AD
patients (Fig 3). Furthermore, under these experimental conditions,
we observed increased expression of IL-13 in AD compared with
NAD patients.
Because NAD patients are not sensitized to aeroallergens and
food antigens, one explanation for the existence and in vivo
activation of T cells in skin lesions of NAD could be their
responsiveness to superantigenic stimuli released by Staphylococcus
aureus colonizing the skin. This was analyzed by stimulating the
T cells from skin biopsies of AD and NAD patients with SEB, by
using irradiated autologous PBMC as antigen-presenting cells. As
shown in Fig 4(A), T cells of both AD and NAD patients responded
to SEB in a concentration-dependent manner. SEB-specific stimula-
tion only involves T cells that express certain Vβ elements of the
TCR. To better quantitate the cytokines expressed by skin T cells,
in vitro-expanded skin T cells were stimulated with the combination
of anti-CD2/anti-CD3/anti-CD28 MoAb for 72 h, and released
cytokines were measured by ELISA. As shown in Fig 4(B),
increased IL-5 and IL-13 concentrations were measured in the
supernatants of AD compared with NAD patients. T cells from
NAD patients, however, also produced detectable amounts of these
two cytokines. In contrast, the released amounts of IFN-γ and IL-4
were less, and no significant differences were found between AD
and NAD patients.
Skin T cells help B cells to produce high amounts of IgE in
AD but not NAD As we had evidence for increased IL-13
expression in AD compared with NAD patients, we hypothesized
that the threshold to help B cells to produce high amounts of IgE
may be reached by skin T cells from AD, but not NAD patients.
As shown in Fig 5, no significant IgE production is observed in
the absence of T cells. Skin T cells from AD patients induced
normal blood B cells to produce significantly high amounts of IgE
in comparison with NAD. Whereas the B cell help of skin T cells
from AD patients could be neutralized by anti-IL-13 MoAb and
recombinant IL-4/IL-13 antagonist, however, the marginal induced
IgE production by NAD T cells could not be blocked by these
reagents. Neutralizing IL-4 by anti-IL-4 MoAb had no effect in
this system. Together, these data suggest that IL-13 is an important
cytokine involved in increased IgE production in AD patients.
Although T cells from NAD patients also produced significant
amounts of IL-13, these levels may not have been elevated enough
to stimulate increased IgE production.
DISCUSSION
A number of immunologic parameters were demonstrated to be
abnormal and related to the clinical severity of allergic and nonaller-
gic forms of AD (Kapp et al, 1988; Rousset et al, 1991; Jujo et al,
1992; Walker et al, 1993; Hamid et al, 1994; Ka¨gi et al, 1994;
Morren et al, 1994; Akdis et al, 1997; Fujimura et al, 1997;
Nakazawa et al, 1997). Based on skin biopsies, the present study
demonstrates that T cells are important pathogenetic factors in both
forms of the disease. The majority of cells in the cellular infiltrate
in AD were T cells. The numbers of infiltrating eosinophils
compared with T cells were marginal in both AD and NAD
patients. This is in contrast to other eosinophilic tissues from
patients with bronchial asthma (Bousquet et al, 1990) or nasal
polyps (Simon et al, 1997).
Allergen-specific T cells derived from skin lesions in patients
with the allergic variant of AD were found to produce predomi-
nantly type 2 Th cytokines (Sager et al, 1992; Van Reijsen et al,
1992). These studies were mainly performed by T cells cloned
after epicutaneous application of inhalant allergens. In contrast,
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Figure 3. Intracytoplasmic cytokine
content of CD4F and CD8F skin
T cells following stimulation with anti-
CD2, anti-CD3, and anti-CD28 MoAb
for 16 h. The results are representative
of four independent experiments in each
group of patients. The skin T cells of AD
patients expressed much more IL-5 and
IL-13 compared with NAD patients. IL-4
expressing cells were ø 3% in both AD
and NAD patients. The expression of
IFN-γ was lower in AD in comparison
with NAD patients.
allergen-specific T cell clones obtained from peripheral blood of
the same patients (Sager et al, 1992) and allergen-specific T cell
clones from chronic lesions and older patch tests displayed IFN-γ
(Werfel et al, 1996). It appears that, the age of the patient population,
the age of the eczema lesion (Hamid et al, 1994), the isolation site
of T cells and T cell cloning procedure might influence the
cytokine pattern of T cells. The present study demonstrates by
immunohistochemistry, flow cytometry, and ELISA measurements,
that, skin T cells from AD and NAD patients produce significant
amounts of IL-5 and IL-13. In all three test systems, AD patients
expressed higher levels of these two cytokines than NAD patients.
In both groups of patients, IL-4 was not significantly expressed by
skin T cells. In contrast to IL-4, IL-13, that can replace IL-4 in
the induction of IgE mRNA (Punnonen et al, 1993), was detected
in skin lesions of both forms of AD; however, The overall IL-13
expression was lower in NAD compared with AD patients. IL-5
was detected in many, but not in all AD and NAD patients. The
Th1 cytokines IL-2 and IFN-γ were both detected in lesional skin,
although the IFN-γ levels were relatively low in both AD and
NAD patients and was slightly increased in NAD compared with
AD patients. Similarly, high amounts of intracytoplasmic IL-5 and
IL-13 were detected in activated skin homing CLA1 T cells of
AD patients purified from peripheral blood (Akdis et al, 1997,
1999). The leukocyte differential blood counts revealed a charac-
teristic blood eosinophilia in both AD and NAD patients, that was
more pronounced in AD compared with NAD patients. High IL-5
production in both forms of AD and even higher levels in allergic
form of AD may suggest a part for blood eosinophilia in both
diseases as demonstrated by delayed apoptosis of blood eosinophils
(Wedi et al, 1997).
The functional IgE regulatory capacity of T cells from skin
lesions of AD patients was investigated by coculturing isolated skin
T cells with purified B cells. The IgE production by B cells mainly
depended on secreted IL-13. A number of studies have shown that
IL-4 plays an important part in the induction of IgE synthesis in
AD in PBMC cultures (Rousset et al, 1991; Jujo et al, 1992;
Morren et al, 1994). Previous reports and our present findings,
however, indicate that IL-4 inhibition is not sufficient to suppress
IgE in atopic diseases. An IgE-inducing activity which could be
attributed to IL-13, was found in PBMC cultures of atopic but
not normal individuals (Zhang et al, 1992; Van der Pouw-Kraan
et al, 1994). In contrast to IL-4, there is no feedback or priming
mechanism exerted by IL-13 on T cells, because human T cells
do not display specific IL-13 receptors (Zurawski et al, 1994).
Figure 4. Superantigen response and cytokine profile of skin T cells
in AD and NAD. There was no difference in SEB induced proliferation
between skin T cells of AD and NAD patients. IL-5 and IL-13 production
following stimulation with anti-CD2, anti-CD3, and anti-CD28 MoAb
for 72 h of the skin T cells from AD patients was significantly high
compared with NAD patients. The levels of released IFN-γ and IL-4 were
low, and no differences were observed between AD and NAD patients.
The data are presented as mean 6 SD of four independent experiments
in each patient group (*p , 0.05).
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Figure 5. Skin T cells from both AD and NAD patients induce IgE
production in T cell-depleted PBMC populations (T Depl. PBMC).
Only the skin T cells from AD patients helped B cells to produce very
high amounts of IgE. The induced IgE production by T cells from
AD patients could be blocked with neutralizing anti-IL-13 MoAb and
recombinant IL-4/IL-13 antagonist (Y124D), suggesting that IL-13 may
play an important part in the induction of IgE synthesis. Results represent
means of triplicate cultures 6 SD from four independent experiments in
each patient group (*p , 0.05).
Similarly, a central role for IL-13 in the expression of murine
asthma is demonstrated (Gru¨nig et al, 1998; Wills-Karp et al, 1998),
suggesting that IL-4 may be decisive at the initial phase of allergic
responses and in the priming and development of Th2 cells (Le Gros
et al, 1990; Jung et al, 1996), whereas IL-13 becomes more
prominent in IgE induction in chronic AD. In addition, IgE Fc
receptor II (CD23) on B cells is significantly expressed in AD
compared with NAD (Ka¨gi et al, 1994). It is known that both IL-4
and IL-13 may upregulate this receptor (Zurawski et al, 1994).
As IL-4 is not expressed in skin T cells, as demonstrated by
immunohistochemistry and intracytoplasmic cytokine staining,
IL-13 appears to be the major cytokine in the activation of B cells
and IgE production in AD. Although IL-13 was produced in
higher amounts in both AD and NAD, B cells of healthy individuals
did not respond to the IL-13 produced from skin T cells of NAD.
This can be ascribed to IL-13 produced over a threshold to activate
B cells in AD. Furthermore, the genetical variations on the quality
of IL-13 produced might play a part in increased activity of the
cytokine. Moreover, the IL-4–IL-13 receptor common α chain
has been demonstrated to have mutations that might induce high
B cell responsiveness to IL-13 in AD (Tony et al, 1994; Aman
et al, 1996).
A number of pathogenetic mechanisms leading to T cell activation
in AD including aeroallergens, food allergens, and superantigens
have been emphasized. The role of aeroallergens and food allergens
in the exacerbation of AD by T cell activation has been extensively
studied (Sager et al, 1992; Van der Heijden et al, 1991; Varney et al,
1993; Abernathy-Carver et al, 1995). It is apparent that allergen-
specific T cell responses in food and aeroallergen allergy are
confined to AD and does not explain the activation and recruitment
of T cells in NAD skin lesions. The present study shows that
T cells isolated from the skin of AD and NAD patients efficiently
proliferate by superantigenic stimulation. From a number of studies
it could be concluded that bacterial superantigens contribute to the
pathogenesis and exacerbation of AD. Staphylococcal superantigens
were isolated from AD skin (Leyden et al, 1974; Kotzin et al, 1993).
Superantigen patch test elicits skin inflammation in AD patients
(Strange et al, 1996) and in human severe combined immuno-
deficiency mouse model (Herz et al, 1998). In addition, super-
antigens upregulate the skin homing ligand (Leung et al, 1995).
Together, these data suggest that bacterial superantigens can lead
to activation and proliferation of T cells in NAD skin as well as
AD skin. The clinical manifestations of NAD were the same as
AD suggesting that mechanisms causing eczema is independent of
IgE overproduction. Provocation factors other than antigens and
superantigens such as emotional factors (Koblenzer, 1983), irritating
substances (Agner, 1991), hormones, and climatic changes (Morren
et al, 1994) were shown to influence the course of eczema. Taken
together, T cells appear to be important players regulating the
inflammatory processes in both AD and NAD patients. This
hypothesis is further supported by the observation that drugs, such
as FK-506, that block the activation of T cells, are effective in AD
treatment (Ruzicka et al, 1997).
In conclusion, we established a role for T cells in the nonallergic
form of AD. Although the cellular infiltrate in lesional skin of both
forms of AD patients contained high numbers of T cells, it appeared
that the expression of cytokines IL-5 and IL-13 as well as the
capacity to produce these cytokines by skin T cells is reduced in
NAD patients. T cells that express low IL-13 are unable to help B
cells to produce large amounts of IgE in NAD patients. The reasons
for the different cytokine expression patterns observed between
the two forms of AD patients could involve underlying genetic
differences or additional factors that limit IL-5 and IL-13 production
at the inflammatory site in NAD patients.
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